Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

Natalizumab dosage suspension: Are we helping or hurting?

(2010) Timothy W. West et al.   ANNALS OF NEUROLOGY

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

(2010) Ernst-Wilhelm Radue et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Combination therapy in multiple sclerosis

(2010) Devon Conway et al.   LANCET NEUROLOGY

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries

(2009) N. Putzki et al.   EUROPEAN JOURNAL OF NEUROLOGY

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

(2009) Richard A Rudick et al.   LANCET NEUROLOGY

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

(2009) R Ellis et al.   Multiple Sclerosis Journal

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina

(2008) A. Carrá et al.   EUROPEAN JOURNAL OF NEUROLOGY

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis

(2008) A Gajofatto et al.   Multiple Sclerosis Journal